Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Bryant E. FongManaging Director
Mr. Fong joined Burrill & Company in 1998 and has more than 15 years of experience in the biotechnology industry. Prior to joining Burrill & Company, Mr. Fong held positions as a biochemist and molecular biologist with two early stage biotechnology companies located in the San Francisco Bay Area. His first position involved working with eukaryotic recombinant expression systems and was part of the first research group to publish on the expression of a four-gene system in S. cerevisiae in the production of recombinant human collagen. Later, Mr. Fong was hired as the first employee of a genomics company to help develop and validate its high-throughput functional genomics platform. Mr. Fong’s aggregate research experiences include recombinant protein expression in yeast, development of linear artificial chromosomes for pathway engineering/heterologous gene transfer in yeast, and catalytic RNA technology. Mr. Fong currently serves on the boards of directors of a number of private companies including Neurotech Pharmaceuticals, Nora Therapeutics, Odyssey Thera, Alinea Pharmaceuticals, Ferrokin Biosciences, NEOS Therapeutics, Logical Therapeutics, and Yaupon Pharmaceuticals (observer).
Mr. Fong earned his bachelors degree with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley.